1. Home
  2. BUDA vs CGTX Comparison

BUDA vs CGTX Comparison

Compare BUDA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUDA

Buda Juice Inc. Common Stock

N/A

Current Price

$7.78

Market Cap

91.7M

ML Signal

N/A

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.89

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUDA
CGTX
Founded
2013
2007
Country
United States
United States
Employees
39
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.7M
102.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BUDA
CGTX
Price
$7.78
$0.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$14.00
$3.33
AVG Volume (30 Days)
21.5K
1.1M
Earning Date
03-26-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.25
$0.55
52 Week High
$12.00
$3.83

Technical Indicators

Market Signals
Indicator
BUDA
CGTX
Relative Strength Index (RSI) 45.43 37.08
Support Level $8.05 $0.55
Resistance Level $10.42 $1.19
Average True Range (ATR) 0.64 0.06
MACD -0.21 -0.00
Stochastic Oscillator 25.71 7.27

Price Performance

Historical Comparison
BUDA
CGTX

About BUDA Buda Juice Inc. Common Stock

Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: